NCT02954926

Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis

Effect of Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 92 (actual)
• Sponsor: Hormozgan University of Medical Sciences · Academic / Other
• Sex: All
• Age: 1 Day – 7 Days
• Healthy volunteers: Not accepted

Summary

Majority of healthcare authorities believe that due to the methodological weakness and small number of patients in conducted therapeutic trials, the evidences are insufficient to support the efficacy of intravenous immunoglobulin (IVIG) in prevention of preterm neonatal sepsis. The objective of this research is to determine the effect of intravenous immunoglobulin in prevention of preterm neonatal sepsis.

Conditions

• Neonatal Sepsis

Interventions

Type	Name	Description
DRUG	IVIG	IVIG at a dose of 500mg/kg within 12 h and 3 days of birth

Timeline

• Start date: 2015-11-01
• Primary completion: 2016-10-01
• Completion: 2016-11-01
• First posted: 2016-11-04
• Last updated: 2016-11-04

Locations

1 site across 1 country: Iran